Patient-derived microtumors grown from tiny needle biopsy samples were reported to predict which breast cancer drugs would work, with results aligning with actual clinical outcomes in a short 2–3 week turnaround. The approach targets the persistent gap between genetic biomarkers and actionable drug response data. Separately, a new iScience study described a pipeline for reproducible tau PET quantification—an open-source workflow intended to standardize analysis and reduce variability across studies. Together, the updates highlight parallel momentum toward faster, more reproducible readouts—one at the bench and one at the imaging analysis layer. For oncology R&D, these developments strengthen the case for combining rapid functional response testing with standardized biomarker quantification.